First-line parp inhibition in ovarian cancer — standard of care for all?

In 2018, the SOLO1 trial set a new standard of care with maintenance olaparib substantially extending progression-free survival (PFS) in women with newly-diagnosed _BRCA1/2_-mutated

advanced-stage ovarian cancer. Herein, we summarize trials of first-line poly(ADP-ribose) polymerase (PARP) inhibition beyond _BRCA1/2_ mutations, including combination strategies, and

discuss the optimum use of PARP inhibition in advanced-stage ovarian cancer. Access through your institution Buy or subscribe This is a preview of subscription content, access via your

institution RELEVANT ARTICLES Open Access articles citing this article. * VEGF PATHWAY INHIBITION POTENTIATES PARP INHIBITOR EFFICACY IN OVARIAN CANCER INDEPENDENT OF BRCA STATUS * Francesca

Bizzaro * , Ilaria Fuso Nerini *  … Raffaella Giavazzi _Journal of Hematology & Oncology_ Open Access 06 November 2021 * CYTOTOXIC AND TARGETED THERAPY FOR BRCA1/2-DRIVEN CANCERS *

Evgeny N. Imyanitov _Hereditary Cancer in Clinical Practice_ Open Access 28 August 2021 ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print issues and online access $209.00 per year only

$17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout

ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * George, A., Kaye, S. & Banerjee, S. Delivering

widespread BRCA testing and PARP inhibition to patients with ovarian cancer. _Nat. Rev. Clin. Oncol._ 14, 284–296 (2017). Article  CAS  Google Scholar  * Moore, K. et al. Maintenance

olaparib in patients with newly diagnosed advanced ovarian cancer. _N. Engl. J. Med._ 379, 2495–2505 (2018). Article  CAS  Google Scholar  * Lord, C. J. & Ashworth, A. Mechanisms of

resistance to therapies targeting BRCA-mutant cancers. _Nat. Med._ 19, 1381–1388 (2013). Article  CAS  Google Scholar  * González-Martín, A. et al. Niraparib in patients with newly diagnosed

advanced ovarian cancer. _N. Engl. J. Med._ 381, 2391–2402 (2019). Article  Google Scholar  * Ray-Coquard, I. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer.

_N. Engl. J. Med._ 381, 2416–2428 (2019). Article  CAS  Google Scholar  * Coleman, R. et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. _N. Engl. J.

Med._ 381, 2403–2415 (2019). Article  CAS  Google Scholar  * Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer

and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. _Lancet Oncol._ 18, 1274–1284 (2017). Article  CAS  Google Scholar  * Matthews, C.

A. et al. Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a in BRCA mutation (BRCAm): Efficacy by surgical and

tumor status in the Phase III SOLO1 trial. _J. Clin. Oncol._ 37 (Suppl. 15), 5541 (2019). Article  Google Scholar  * Oaknin, A. et al. Time to second progression (PFS2) and second subsequent

therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial. _Ann.

Oncol._ 30 (Suppl. 5), mdz250.003 (2019). Google Scholar  Download references ACKNOWLEDGEMENTS The authors acknowledge the National Institute for Health Research, Royal Marsden and ICR

Biomedical Research Centre for Cancer. The work of C.J.L. is funded by Breast Cancer Now as part of Programme Funding to the Breast Cancer Now Toby Robins Research Centre (CTR-Q4-Y2) and by

a Cancer Research UK Programme Grant (CRUK/A14276). AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK Susana

N. Banerjee * Breast Cancer Now Toby Robins Research Centre and Cancer Research UK Gene Function Laboratory, Institute of Cancer Research, London, UK Christopher J. Lord Authors * Susana N.

Banerjee View author publications You can also search for this author inPubMed Google Scholar * Christopher J. Lord View author publications You can also search for this author inPubMed 

Google Scholar CORRESPONDING AUTHOR Correspondence to Susana N. Banerjee. ETHICS DECLARATIONS COMPETING INTERESTS S.B. has received honoraria as an advisory board member and/or giving

lectures for AstraZeneca, Clovis, Genmabs, Merck Serono, Pharmamar, Roche, Seattle Genetics and Tesaro/GSK. C.J.L. has received research funding from Artios, AstraZeneca and Merck KGaA; has

received honoraria as a consultant or senior advisory board for Artios, AstraZeneca, Gerson Lehrman Group, Merck KGaA, Ono Pharma, Sun Pharma, Syncona, Tango, Third Rock and Vertex; owns

stock in Ovibio and Tango; and is a named inventor on patents describing the use of DNA repair inhibitors and stands to gain from the development as part of the ICR Rewards to Inventors

scheme. SUPPLEMENTARY INFORMATION SUPPLEMENTARY TABLE 1 RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Banerjee, S.N., Lord, C.J. First-line PARP

inhibition in ovarian cancer — standard of care for all?. _Nat Rev Clin Oncol_ 17, 136–137 (2020). https://doi.org/10.1038/s41571-020-0335-9 Download citation * Published: 12 February 2020 *

Issue Date: March 2020 * DOI: https://doi.org/10.1038/s41571-020-0335-9 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link

Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative